ESOPHAGOGASTRIC JUNCTION CANCER
Clinical trials for ESOPHAGOGASTRIC JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC JUNCTION CANCER trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Genetically modified immune cells take on eight cancer types in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…
Matched conditions: ESOPHAGOGASTRIC JUNCTION CANCER
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Triple therapy aims to outsmart stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…
Matched conditions: ESOPHAGOGASTRIC JUNCTION CANCER
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC